GlassScriptPhysician profile
Chad H Dunkle
NPI 1275532590
$6,847.30
in general payments reported to CMS, 2019-2025
43 companies · $14.56 in 2025
The $14.56 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $830 · 2021: $1,117 · 2022: $1,448 · 2023: $1,878 · 2024: $35.18 · 2025: $14.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $798.57 | 2019-2023 | Xarelto |
| Abbvie INC. | $756.30 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $529.26 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $517.75 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $503.71 | 2019-2023 | Farxiga, Breztri |
| Astellas Pharma US INC | $363.98 | 2019-2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.96 | 2019-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $293.58 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $292.88 | 2019-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $278.96 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.23 | 2021-2023 | |
| Pfizer INC. | $219.22 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $197.15 | 2019-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $156.40 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.59 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Dunkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.